CervoMed Inc. reported a net loss of $27.0 million for 2025, a sharp increase from the $16.2 million loss recorded in 2024. The company’s earnings per share fell to a loss of $0.88, missing the consensus estimate of a $0.79 loss by $0.09. Revenue for the year was $0.01 million, a dramatic miss against the $0.84 million consensus estimate, reflecting the end of grant funding from the RewinD‑LB trial’s randomized and extension phases.
Cash, cash equivalents and marketable securities stood at $20.9 million as of December 31 2025, down from $38.9 million a year earlier. Grant revenue dropped to $4.0 million from $9.7 million in 2024, while research and development expenses rose to $21.8 million and general‑administrative costs increased to $10.5 million, bringing total operating expenses to $32.3 million.
The revenue miss is largely attributable to the completion of the RewinD‑LB trial’s grant funding, which had previously supported the company’s operating budget. The EPS miss is a consequence of both the revenue shortfall and the higher operating expenses, which together widened the net loss and pushed earnings below analyst expectations.
CervoMed’s cash position has been described as a critical concern, with only about six months of operating runway remaining. The company is actively pursuing additional financing to support its planned Phase 3 trial in dementia with Lewy bodies, a key milestone for its lead candidate, neflamapimod.
Investors have reacted with caution, citing the missed earnings and revenue estimates and the limited cash reserves as key risks. The company’s guidance for the next quarter or full year 2026 was not disclosed, leaving uncertainty about future performance.
The company remains focused on advancing its Phase 3 program, but the financial results underscore the urgency of securing new capital to sustain operations and complete the trial.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.